PL348575A1 - Controlled release formulation comprising gnrh-ii - Google Patents

Controlled release formulation comprising gnrh-ii

Info

Publication number
PL348575A1
PL348575A1 PL99348575A PL34857599A PL348575A1 PL 348575 A1 PL348575 A1 PL 348575A1 PL 99348575 A PL99348575 A PL 99348575A PL 34857599 A PL34857599 A PL 34857599A PL 348575 A1 PL348575 A1 PL 348575A1
Authority
PL
Poland
Prior art keywords
gnrh
controlled release
release formulation
formulation
controlled
Prior art date
Application number
PL99348575A
Inventor
Steve Qi
Karen Akinsanya
Amanda Hayward
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of PL348575A1 publication Critical patent/PL348575A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PL99348575A 1998-12-03 1999-12-02 Controlled release formulation comprising gnrh-ii PL348575A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9826662A GB2344287A (en) 1998-12-03 1998-12-03 Controlled release pharmaceutical formulation
PCT/GB1999/004045 WO2000032218A1 (en) 1998-12-03 1999-12-02 Controlled release formulation comprising gnrh-ii

Publications (1)

Publication Number Publication Date
PL348575A1 true PL348575A1 (en) 2002-06-03

Family

ID=10843631

Family Applications (1)

Application Number Title Priority Date Filing Date
PL99348575A PL348575A1 (en) 1998-12-03 1999-12-02 Controlled release formulation comprising gnrh-ii

Country Status (22)

Country Link
EP (1) EP1140133A1 (en)
JP (1) JP2002531411A (en)
KR (1) KR20010089538A (en)
CN (1) CN1332635A (en)
AU (1) AU770676B2 (en)
BR (1) BR9915943A (en)
CA (1) CA2353798A1 (en)
CZ (1) CZ20011893A3 (en)
EE (1) EE200100293A (en)
GB (1) GB2344287A (en)
HR (1) HRP20010421A2 (en)
HU (1) HUP0104943A3 (en)
IL (1) IL143496A0 (en)
MX (1) MXPA01005543A (en)
NO (1) NO20012636L (en)
NZ (1) NZ511984A (en)
PL (1) PL348575A1 (en)
RU (1) RU2233170C2 (en)
SK (1) SK7552001A3 (en)
TR (1) TR200102273T2 (en)
WO (1) WO2000032218A1 (en)
ZA (1) ZA200104530B (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1909814B1 (en) * 2005-07-26 2015-06-24 Georg-August-Universität Göttingen Stiftung öffentlichen Rechts (ohne Bereich Humanmedizin) Peptides for induction and enhancement of apoptosis in tumor cells
GB0616111D0 (en) 2006-06-16 2006-09-20 Ardana Bioscience Ltd Agents, methods and uses
WO2010111617A2 (en) 2009-03-27 2010-09-30 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
WO2011032099A1 (en) 2009-09-11 2011-03-17 The Board Of Trustees Of The University Of Illinois Methods of treating diastolic dysfunction and related conditions
US20120208762A1 (en) 2009-10-27 2012-08-16 The Board Of Trustees Of The University Of Illinois Methods of Diagnosing Diastolic Dysfunction
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
KR20120123443A (en) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon antagonist - gip agonist conjugates and composition for the treatment of metabolic disorders and obesity
ES2575160T3 (en) 2010-03-15 2016-06-24 The Board Of Trustees Of The University Of Illinois Inhibitors of the interactions that bind the alpha subunit of beta integrin-protein G
JP5969469B2 (en) 2010-06-16 2016-08-17 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Single-chain insulin agonist with high activity for insulin receptor
US20120004182A1 (en) 2010-07-02 2012-01-05 Carsten Gruendker Pharmaceutical compositions and methods for induction and enhancement of apoptosis in tumor cells
WO2012087943A2 (en) 2010-12-20 2012-06-28 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
RS56173B1 (en) 2011-06-22 2017-11-30 Univ Indiana Res & Tech Corp GLUCAGON / GLP-1 RECEPTOR RECEPTOR COAGONISTS
US9415123B2 (en) 2011-10-10 2016-08-16 The Regents Of The University Of Michigan Polymeric nanoparticles for ultrasound imaging and therapy
JP6324315B2 (en) 2011-11-17 2018-05-16 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Glucagon superfamily of peptides exhibiting glucocorticoid receptor activity
BR112014015156A2 (en) 2011-12-20 2020-10-27 Indiana University Research And Technology Corporation ctp-based insulin analogues, their methods of production and use in the treatment of hyperglycemia, as well as nucleic acid and host cell sequences
CN104619350A (en) 2012-06-14 2015-05-13 Ambrx公司 Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
PE20150863A1 (en) 2012-06-21 2015-06-11 Univ Indiana Res & Tech Corp GLUCAGON ANALOGS DISPLAYING GIP RECEPTOR ACTIVITY
CN104583232B (en) 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 Show the glucagon analogs of GIP receptor actives
EP3395358B1 (en) 2012-09-26 2019-11-06 Indiana University Research and Technology Corporation Insulin analog dimers
JP6538645B2 (en) 2013-03-14 2019-07-03 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Insulin-incretin complex
US10189908B2 (en) 2014-02-05 2019-01-29 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
CN108271356A (en) 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 incretin-insulin conjugate
WO2016123143A1 (en) 2015-01-26 2016-08-04 The University Of Chicago CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2
CN107683289B (en) 2015-01-26 2021-08-06 芝加哥大学 IL13Rα2 binding agents and their use in cancer therapy
CN104789524A (en) * 2015-04-30 2015-07-22 四川大学 Osteoporotic rat primary osteoblasts isolated culture method and application thereof
WO2017024111A1 (en) 2015-08-04 2017-02-09 The University Of Chicago Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6
JP2020505379A (en) * 2017-01-20 2020-02-20 イミューン システム レギュレェイション ホールディング エービー Novel compound (immunorelin)
DK3645002T3 (en) 2017-06-30 2024-12-16 Amgen Inc METHODS FOR TREATING HEART FAILURE WITH CARDIAC SARCOMA ACTIVATORS
EP4029877B1 (en) 2017-08-03 2024-01-17 Amgen Inc. Interleukin-21 muteins and methods of treatment
AU2018329920B2 (en) 2017-09-08 2022-12-01 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
NO20210351A1 (en) 2017-09-18 2021-03-18 Univ California Claudin6 antibodies and methods of treating cancer
TW201930344A (en) 2018-01-12 2019-08-01 美商安進公司 Anti-PD-1 antibodies and methods of treatment
WO2020055913A1 (en) 2018-09-10 2020-03-19 Cardax, Inc. Methods of reducing- c-reactive protein and/or treating cardiovascular disease
US20220177583A1 (en) 2019-03-20 2022-06-09 The Regents Of The University Of California Claudin-6 bispecific antibodies
DK3941946T3 (en) 2019-03-20 2025-03-24 Univ California CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES
WO2020196946A1 (en) * 2019-03-26 2020-10-01 노벨파마 주식회사 Long-acting fatty acid-binding gnrh derivative and pharmaceutical composition comprising same
EP3952841A1 (en) 2019-04-09 2022-02-16 The Board Of Trustees Of The University Of Illinois Drug adsorbed highly porous activated carbon for enhanced drug delivery
US20230190725A1 (en) 2019-04-29 2023-06-22 The Board Of Trustees Of The University Of Illinois Mek inhibitors for corneal scarring and neovascularization
JP2022530241A (en) 2019-04-30 2022-06-28 インスチトゥート デ メディシーナ モリクラール ジョアン ロボ アントゥネス RANK pathway inhibitor combined with CDK inhibitor
JP7763666B2 (en) 2019-06-24 2025-11-04 アムジェン インコーポレイテッド Inhibition of SIRPγ for cancer treatment
CA3151422A1 (en) 2019-08-30 2021-03-04 Research Institute At Nationwide Children's Hospital Copper-atsm for treating neurodegenerative disorders associated with mitochondrial dysfunction
TW202216778A (en) 2020-07-15 2022-05-01 美商安進公司 Tigit and cd112r blockade
DK4243825T3 (en) 2020-11-12 2025-12-01 Amgen Inc OMECAMTIV MECARBIL FOR THE TREATMENT OF HEART FAILURE IN SELECTED PATIENT GROUPS
US20250282870A1 (en) 2021-01-20 2025-09-11 Bioentre Llc Ctla4-binding proteins and methods of treating cancer
WO2023137161A1 (en) 2022-01-14 2023-07-20 Amgen Inc. Triple blockade of tigit, cd112r, and pd-l1
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH661206A5 (en) * 1983-09-23 1987-07-15 Debiopharm Sa PROCESS FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF HORMONDEPENDENT DISEASES.
DE3414595A1 (en) * 1984-04-18 1985-10-31 Hoechst Ag, 6230 Frankfurt USE OF GONADOLIBERIN AND GONADOLIBERINAGONISTS FOR TREATING CLIMATE COMPLAINTS
US4540513A (en) * 1984-09-25 1985-09-10 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Decapeptide having gonadotropin releasing activity
US4721775A (en) * 1985-08-26 1988-01-26 Board Of Regents, The University Of Texas System Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids
DE3634435A1 (en) * 1986-10-09 1988-04-14 Hoechst Ag ANALOGA OF GONADOLIBERIN WITH IMPROVED SOLUBILITY, METHOD FOR THE PRODUCTION THEREOF, THE CONTAINERS THEREOF AND THEIR USE
ZA918168B (en) * 1990-10-16 1993-04-14 Takeda Chemical Industries Ltd Prolonged release preparation and polymers thereof.
IT1243390B (en) * 1990-11-22 1994-06-10 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION.
CA2192773C (en) * 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
AU3388597A (en) * 1996-06-13 1998-01-07 University Of Cape Town Human type ii gonadotropin-releasing hormone receptor
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
GB2343182A (en) * 1998-10-27 2000-05-03 Ferring Bv Use of GnRH-II and analogues thereof for the treatment of osteoporosis

Also Published As

Publication number Publication date
CN1332635A (en) 2002-01-23
HUP0104943A3 (en) 2002-08-28
WO2000032218A1 (en) 2000-06-08
AU1573200A (en) 2000-06-19
IL143496A0 (en) 2002-04-21
AU770676B2 (en) 2004-02-26
BR9915943A (en) 2001-08-21
GB9826662D0 (en) 1999-01-27
HUP0104943A2 (en) 2002-06-29
CA2353798A1 (en) 2000-06-08
MXPA01005543A (en) 2003-07-14
KR20010089538A (en) 2001-10-06
NZ511984A (en) 2002-11-26
EP1140133A1 (en) 2001-10-10
HRP20010421A2 (en) 2002-06-30
NO20012636L (en) 2001-07-12
SK7552001A3 (en) 2002-02-05
GB2344287A (en) 2000-06-07
JP2002531411A (en) 2002-09-24
NO20012636D0 (en) 2001-05-29
RU2233170C2 (en) 2004-07-27
EE200100293A (en) 2002-08-15
TR200102273T2 (en) 2001-12-21
CZ20011893A3 (en) 2002-05-15
ZA200104530B (en) 2002-06-04

Similar Documents

Publication Publication Date Title
IL143496A0 (en) Controlled release formulation comprising gnrh-ii
EG24198A (en) Extended release formulation
SG71879A1 (en) Controlled release compositions
SG93831A1 (en) Polimeric controlled release compositions
PL343021A1 (en) Formulations
SG71789A1 (en) Controlled release compositions
PL346423A1 (en) Microcapsule formulations
EG24226A (en) Formulation
IL135457A0 (en) Extended release formulation
PL346414A1 (en) Microcapsule formulations
SG72947A1 (en) Controlled release compositions
GB9905898D0 (en) Controlled-dose formulation
GB9902304D0 (en) Formulation
AUPP279698A0 (en) Sustained release formulation
GB2334486B (en) Release unit
GB2322867B (en) Release agent
GB9810180D0 (en) Novel formulation
GB9815002D0 (en) Formulations
GB9927614D0 (en) Sterliant formulation
GB9815001D0 (en) Formulations
GB9711946D0 (en) Release devices
GB9816563D0 (en) Controlled release formulations
GB9404544D0 (en) Controlled release formulation
GB9902236D0 (en) Formulation
GB9916958D0 (en) Controlled release formulations

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)